Prihlásiť sa Zaregistrujte sa zadarmo

Dlh / vlastný kapitál spoločnosti Abeona Therapeutics Inc

Aká je hodnota metriky Dlh / vlastný kapitál spoločnosti Abeona Therapeutics Inc?

Hodnota metriky Dlh / vlastný kapitál spoločnosti Abeona Therapeutics Inc je 3.32

Aká je definícia metriky Dlh / vlastný kapitál?



Dlh / vlastný kapitál (Debt to equity ratio) ukazovateľ vyjadruje pomer vlastného kapitálu a cudzích zdrojov na financovanie majetku spoločnosti.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dlh / vlastný kapitál spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc

Čomu sa venuje spoločnosť Abeona Therapeutics Inc?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t

Firmy s metrikou dlh / vlastný kapitál podobnou spoločnosti Abeona Therapeutics Inc



  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Core-Mark Hldg Co Inc je 3.31
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Haitong International Securities je 3.31
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Wall je 3.31
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Southern je 3.31
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Puma Biotechnology Inc je 3.31
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Haitong Securities Co je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Abeona Therapeutics Inc je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Grammer AG je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Butn je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti GAM AG je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti HeraMED je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti Great Ajax Corp je 3.32
  • Hodnota metriky Dlh / vlastný kapitál spoločnosti HENSOLDT GmbH je 3.32